Profile data is unavailable for this security.
About the company
Medivir AB is a Sweden-based pharmaceutical research and development company with focus on oncology. The Company specializes in protease inhibitor design and nucleoside and nucleotide science, applying it to development of therapies for cancers with unmet medical need. The Company's clinical pipeline consists of remetinostat, a topical histone deacetylase (HDAC) inhibitor in phase II of clinical studies for the treatment of cutaneous T-cell lymphoma (CTCL), birinapant in combination with Keytruda (pembrolizumab) in phase I of clinical studies for the treatment of solid tumors, MIV-818, a nucleotide-based prodrug in phase I of clinical trials for the treatment of liver cancer, and MIV-711, a cathepsin K (CTSK) inhibitor in IIa extension study for the treatment of osteoarthritis. Furthermore, the Company has additional research projects in cooperation with other institutions.
- Revenue in SEK (TTM)6.83m
- Net income in SEK-105.92m
- Incorporated1987
- Employees10.00
- LocationMedivir ABLunastigen 5, 2 trHUDDINGE 141 22SwedenSWE
- Phone+46 854683100
- Fax+46 84076439
- Websitehttps://www.medivir.se/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Xintela AB | 381.00k | -40.83m | 274.14m | -- | -- | -- | -- | 719.53 | -0.0817 | -0.0817 | 0.0008 | -0.0319 | 0.0306 | -- | 0.0493 | -- | -327.65 | -181.06 | -- | -391.61 | 100.00 | -- | -10,717.06 | -235,894.00 | -- | -203.91 | -- | -- | -- | -45.54 | 18.32 | -- | -61.47 | -- |
| Intervacc AB | 9.78m | -102.66m | 274.17m | 15.00 | -- | 1.35 | -- | 28.04 | -1.36 | -1.36 | 0.1291 | 2.68 | 0.0355 | 3.19 | 1.62 | 651,933.30 | -37.23 | -17.62 | -40.38 | -18.77 | -551.10 | -243.59 | -1,049.76 | -626.90 | 2.90 | -- | 0.0006 | -- | -17.23 | -25.79 | -60.31 | -- | -38.72 | -- |
| Abliva AB | 137.00k | -102.13m | 293.04m | 6.00 | -- | 2.85 | -- | 2,138.98 | -0.0928 | -0.0928 | 0.0001 | 0.0638 | 0.0013 | -- | 0.0062 | -- | -93.81 | -74.59 | -103.87 | -86.98 | -35,826.28 | -- | -74,542.34 | -65,958.89 | -- | -- | 0.00 | -- | 341.94 | 93.89 | -12.02 | -- | -19.74 | -- |
| Annexin Pharmaceuticals AB (publ) | 0.00 | -52.36m | 300.60m | 4.00 | -- | 8.34 | -- | -- | -0.1873 | -0.1873 | 0.00 | 0.0676 | 0.00 | -- | -- | 0.00 | -162.59 | -125.42 | -220.41 | -151.33 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -8.17 | -- | -- | -- |
| Lifecare ASA | 15.64m | -50.32m | 314.14m | 32.00 | -- | 2.62 | -- | 20.09 | -0.3152 | -0.3152 | 0.0999 | 0.632 | 0.1564 | -- | -- | 502,995.00 | -50.29 | -40.00 | -56.16 | -45.26 | -- | -- | -321.48 | -175.53 | -- | -- | 0.0918 | -- | -40.88 | 30.29 | -101.74 | -- | -- | -- |
| Curasight A/S | -43.18m | -48.24m | 327.05m | 4.00 | -- | 16.98 | -- | -- | -1.51 | -1.51 | -1.35 | 0.6008 | -0.7563 | -- | -- | -7,107,500.00 | -84.49 | -24.61 | -111.31 | -26.01 | -- | -- | -- | -- | -- | -32.26 | 0.4439 | -- | -123.97 | -- | -42.62 | -- | -- | -- |
| Herantis Pharma Oyj | 0.00 | -6.94m | 335.75m | 10.00 | -- | 14.53 | 14.28 | -- | -0.0146 | -0.0146 | 0.00 | 0.1012 | 0.00 | -- | -- | 0.00 | -13.93 | -80.46 | -27.32 | -104.37 | -- | -- | -- | -- | -- | -- | 0.0145 | -- | -- | -- | 103.00 | -- | -- | -- |
| Alzinova AB | 300.00k | -18.12m | 338.83m | 5.00 | -- | 2.01 | -- | 1,129.43 | -0.332 | -0.332 | 0.0055 | 1.89 | 0.0025 | -- | 0.4752 | 60,000.00 | -15.15 | -10.77 | -15.91 | -11.27 | -2,621.00 | -- | -6,039.67 | -18,447.90 | -- | -392.89 | 0.0076 | -- | -- | -- | -25.92 | -- | 15.81 | -- |
| Medivir AB | 6.83m | -105.92m | 360.06m | 10.00 | -- | 2.05 | -- | 52.69 | -1.45 | -1.45 | 0.0824 | 1.57 | 0.0311 | -- | 1.12 | 683,300.00 | -48.26 | -28.91 | -61.14 | -34.77 | -1,152.23 | -467.42 | -1,550.15 | -675.96 | -- | -- | 0.0543 | -- | 73.16 | -20.39 | -0.6275 | -- | -47.96 | -- |
| Lytix Biopharma AS | -97.14bn | -97.14bn | 372.04m | 10.00 | -- | 6.47 | -- | -- | -- | -- | -- | 1.19 | -- | -- | -- | -- | -- | -56.91 | -- | -65.83 | -- | -- | -- | -771.78 | -- | -- | 0.0482 | -- | -63.82 | 63.94 | -56.77 | -- | -- | -- |
| Initiator Pharma A/S | 0.00 | -25.70m | 383.30m | 3.00 | -- | 14.13 | -- | -- | -0.4684 | -0.4684 | 0.00 | 0.5125 | 0.00 | -- | -- | 0.00 | -65.39 | -68.27 | -73.28 | -74.02 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 27.95 | -- | -- | -- |
| Bergenbio ASA | 506.10k | -150.96m | 399.82m | 15.00 | -- | 2.35 | -- | 789.99 | -5.37 | -5.37 | 0.018 | 4.48 | 0.0023 | -- | 0.0411 | 20,840.00 | -67.73 | -66.15 | -85.55 | -78.74 | -- | -- | -29,828.21 | -11,419.44 | -- | -- | 0.00 | -- | -9.00 | -31.43 | 36.98 | -- | -- | -- |
| SynAct Pharma AB | 0.00 | -165.96m | 413.38m | 5.00 | -- | 2.21 | -- | -- | -4.75 | -4.75 | 0.00 | 4.53 | 0.00 | -- | -- | 0.00 | -61.52 | -125.17 | -67.60 | -151.70 | -- | -- | -- | -- | -- | -231.85 | 0.0076 | -- | -- | -- | -117.54 | -- | -- | -- |
| Mendus AB (publ) | 0.00 | -141.42m | 427.96m | 28.00 | -- | 0.6128 | -- | -- | -3.54 | -3.54 | 0.00 | 13.87 | 0.00 | -- | -- | 0.00 | -21.08 | -18.84 | -23.01 | -20.21 | -- | -- | -- | -28,474.53 | -- | -- | 0.0318 | -- | -100.00 | -- | 26.78 | -- | -- | -- |
| Guard Therapeutics Intrntnl AB (publ) | 0.00 | -78.82m | 433.21m | 6.00 | -- | 4.56 | -- | -- | -7.83 | -7.83 | 0.00 | 6.45 | 0.00 | -- | -- | -- | -70.61 | -69.56 | -86.38 | -78.62 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -0.4289 | -- | -- | -- |
| Hamlet BioPharma AB | 0.00 | -41.82m | 444.62m | 7.00 | -- | -- | -- | -- | -0.2756 | -0.2756 | 0.00 | -- | -- | -- | -- | 0.00 | -- | -80.47 | -- | -97.51 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -104.57 | -- | -- | -- |
Data as of Sep 24 2024. Currency figures normalised to Medivir AB's reporting currency: Swedish Krona SEK
16.52%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Nordea Investment Management ABas of 29 Apr 2024 | 10.23m | 9.13% |
| Healthinvest Partners ABas of 28 Mar 2024 | 4.90m | 4.38% |
| �landsbanken Abp (Private Banking)as of 28 Mar 2024 | 1.24m | 1.10% |
| Skandia Investment Management ABas of 31 May 2024 | 748.37k | 0.67% |
| Handelsbanken Fonder ABas of 31 Jul 2024 | 665.48k | 0.59% |
| FCG Fonder ABas of 31 Dec 2023 | 273.05k | 0.24% |
| SEB Investment Management ABas of 28 Jun 2024 | 271.87k | 0.24% |
| Storebrand Asset Management ASas of 30 Jun 2024 | 108.42k | 0.10% |
| Dimensional Fund Advisors Ltd.as of 31 May 2024 | 43.61k | 0.04% |
| Skandia Fonder ABas of 31 May 2024 | 20.37k | 0.02% |
More ▼
Data from 28 Mar 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
